Compare Motorola Solutions Inc (MSI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Motorola Solutions Inc vs Novartis AG — how do they compare? Motorola Solutions Inc trades at $463.3 (market cap $76.62B), while Novartis AG trades at $138.16 (market cap $262.64B). The key difference: Novartis AG is far larger — about 3.4× Motorola Solutions Inc's market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| MSI | NVS | |
|---|---|---|
Market Cap | $76.62B | $262.64B |
Sector | Technology | Health |
52-Week High | $491.24 | $168.62 |
52-Week Low | $363.83 | $121.80 |
Enterprise Value | $85.53B | $303.97B |
Dividend Yield | 1.05% | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $462.98, down 1.08% today, with strong technical support at $459 and bullish moving averages. The company shows robust fundamentals with Q2 2026 EPS beating expectations at $4.41 vs. $3.85, revenue growth to $11.68B in 2025, and a $2B share repurchase authorization announced September 2026. Recent acquisition of D-Fend Solutions for $1.5B expands counter-drone capabilities.
Outlook remains positive with 70.6% analyst buy ratings and $536.50 consensus price target, representing 16% upside. Risks include elevated valuation multiples (P/E 36.48) and significant capital expenditures driving negative cash flow. The stock offers growth potential through security technology expansion but faces execution risks from recent acquisitions and competitive pressures.
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
